A previous study performed by our group found 12.8% of clinically high-risk Chinese probands with breast and/or ovarian cancers carried a deleterious BRCA mutation, of which 60.7% were BRCA2 mutations [29]. The gene discussed is BRCA2; the disease is ovarian carcinoma.